Rexahn Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing best-in-class therapeutics for the treatment of cancer. The Company's clinical development programs directly target specific proteins that are selectively expressed in human cancer cells, resulting in increased efficacy and reduced toxicity. In preclinical studies these drug candidates are effective against multiple drug resistant cancers and have shown to increase the effectiveness of various FDA approved cancer treatments. Rexahn is also developing specific biomarker tests that will help identify which patients will be most responsive to its treatments. The Company’s nanotechnology-based drug delivery system has shown it can make FDA approved chemotherapy drugs more effective.
Type
Public
HQ
Rockville, US
Founded
2001
Size (employees)
20 (est)
Website
rexahn.com
Rexahn Pharmaceuticals was founded in 2001 and is headquartered in Rockville, US
Report incorrect company information

Rexahn Pharmaceuticals Office Locations

Rexahn Pharmaceuticals has an office in Rockville
Rockville, US (HQ)
15245 Shady Grove Road
Show all (1)
Report incorrect company information

Rexahn Pharmaceuticals Financials and Metrics

Rexahn Pharmaceuticals Financials

USD

Net income (Q1, 2018)

(2.1 m)

EBIT (Q1, 2018)

(5.9 m)

Market capitalization (21-May-2018)

72.4 m

Closing share price (21-May-2018)

2.3

Cash (31-Mar-2018)

6.3 m
Rexahn Pharmaceuticals's current market capitalization is $72.4 m.
Annual
USDFY, 2015FY, 2016FY, 2017

General and administrative expense

6.1 m6.3 m6.6 m

R&D expense

12.1 m10.1 m10.7 m

Operating expense total

18.3 m16.4 m17.4 m

EBIT

(18.3 m)(16.4 m)(17.4 m)
Quarterly
USDQ3, 2013Q1, 2014Q1, 2018

General and administrative expense

932.8 k1.4 m1.8 m

R&D expense

781.3 k1.3 m4.1 m

Operating expense total

1.8 m2.8 m5.9 m

EBIT

(1.8 m)(2.8 m)(5.9 m)
Annual
USDFY, 2015FY, 2016FY, 2017

Cash

10.2 m11.6 m8.9 m

Inventories

1.2 m608.5 k

Current Assets

24.7 m20.9 m28.1 m

Total Assets

24.8 m21 m28.3 m
Quarterly
USDQ3, 2013Q1, 2014Q1, 2018

Cash

14.9 m40.1 m6.3 m

Current Assets

15.5 m40.9 m22.4 m

Total Assets

16.1 m41.1 m22.6 m

Accounts Payable

750.2 k878.5 k3 m
Annual
USDFY, 2015FY, 2016FY, 2017

Net Income

(14.4 m)(9.3 m)(25.3 m)

Depreciation and Amortization

27.5 k32.9 k42.4 k

Accounts Payable

202 k(778.8 k)1.4 m

Cash From Operating Activities

(17.4 m)(13.2 m)(15.4 m)
Quarterly
USDQ3, 2013Q1, 2014Q1, 2018

Net Income

(6.8 m)(14.6 m)(2.1 m)

Depreciation and Amortization

28.2 k9 k14.6 k

Accounts Payable

(101.6 k)(55.3 k)(184.9 k)

Cash From Operating Activities

(5.7 m)(2.6 m)(5.6 m)
USDY, 2018

Financial Leverage

1.5 x
Show all financial metrics

Rexahn Pharmaceuticals Operating Metrics

FY, 2016

Patent Portfolios

3

Patents and Patent Applications

7

Phase II Trials Products

3

Preclinical Phase Products

1
Show all operating metrics
Report incorrect company information